LC-MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-28. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
| Property | Value | Notes |
|---|---|---|
| Molecular target | HGF/c-Met pathway | Proposed, not fully confirmed |
| Research models | Rodent cognition assays | Results vary by study |
| Human trial data | Limited or absent | No approved clinical use |
| Metabolic stability | Uncertain | Peptide degradation possible |
| Blood-brain barrier | Under investigation | Lipophilicity may affect distribution |
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Hyperinsulinism has also been implicated as a contributing factor in the excessive production of androgens in polycystic ovary syndrome. The principal treatments of hyperinsulinism due to insulin resistance are measures that improve insulin sensitivity, such as weight loss, physical exercise, and drugs such as thiazolidinediones or metformin.
In October 2015, Sam was appointed Senior Playing Coach of the Launceston Football Club returning to his home state and his junior club, where he played the majority of his junior football. Sam's original junior club – Tamar Cats – were based near his home town of Beauty Point. Lonergan, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his teammates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 TSL season. He returned to Launceston as playing coach after his suspension. In 2020 Lonergan became an assistant coach at the Richmond Football Club focusing on midfield development for 1-4 year players. He is the uncle of Gold Coast's Jesse Lonergan.
=== Biphasic half-life === Many drugs show a biphasic decline in plasma concentration after a dose: a steep distribution phase as drug leaves the central compartment for tissues (α phase), followed by a shallower elimination phase as drug is cleared (β phase). On a semi-log plot the two phases are approximately linear, with slopes α and β, and corresponding half-lives t1/2α = 0.693/α and t1/2β = 0.693/β. For single doses of lipophilic, multi-compartment drugs, clinical duration after onset is often driven by the distribution (α) phase, because by the time distribution equilibrium is reached plasma levels are frequently below any minimal effective concentration, so the terminal β phase has little bearing on observable effects. As a result, classifying drugs by terminal (β) half-life can poorly predict duration of action, whereas α half-life is often more informative—though less commonly reported in labels and reviews. Exceptions exist when elimination is extremely rapid: for very short-acting agents, the β phase can meaningfully shorten effect duration even after a single dose (e.g., triazolam, midazolam). The longer half-life is called the terminal half-life and the half-life of the largest component is called the dominant half-life. For a more detailed description see Pharmacokinetics § Multi-compartmental models.
== Honors and awards == 2005 – HUPO Award 2006 – Buchner Medal 2008 – In recognition of his contribution to the field of protein sciences and proteomics the Association of Biomolecular Resource Facilities (ABRF) selected him for the ABRF 2008 Award. 2010 – Herbert A. Sober Lectureship 2010 – Otto Naegeli Prize 2012 – Thomson Medal Award 2014 – he became a member of the German Academy of Sciences Leopoldina. 2015 – ranked #1 on the 2015 list of "most influential people in the analytical sciences" (by the Analytical Scientist) 2018 – Bijvoet Medal of the Bijvoet Center for Biomolecular Research of Utrecht University 2020 – Marcel Benoist Prize 2026 – Canada Gairdner International Award
=== Rail freight === South Africa has a longer rail network than all other Sub-Saharan African countries combined, at a total length of 23,000 km. Its network also features most of the double track rail in the region. State-owned Transnet Freight Rail is one of the largest players in the region. Approximately 15% of SA's land freight moves by rail. As of 2026, South Africa has three "Bulk Mineral Rail Corridors", which are dedicated heavy haul lines for export minerals. These routes, which total 2,241km, are:
Sources: en.wikipedia.org
== Civilian use == MREs have also been distributed to civilians during natural disasters. The National Guard has provided MREs to the public during natural disasters, such as Hurricanes Katrina, Ike, Maria and Sandy; and the 2011 Super Outbreak. The large number of civilians exposed to MREs prompted several jokes during the recent Mardi Gras in New Orleans, with revellers donning clothing made of MRE packets with phrases such as "MRE Antoinette" (referring to Marie Antoinette; the wife of King Louis XVI) and "Man Ready to Eat". The use of rations for noncombat environments has been questioned. While the nutritional requirements are suitable for a combat environment where servicemembers will burn many calories and lose much sodium through sweat, it has been provided as emergency food or even as a standard meal. The high-fat (averaging about 52 grams of fat, 5 grams trans fats) and high-salt content (averaging about 2 grams) are less than ideal for sedentary situations. In the aftermath of Hurricane Katrina, a 77-year-old civilian man with prior congestive heart failure ended up with volume overload from the high sodium content of MREs. The HDR and TOTM account for this nutritional need. Civilian taste-testing of MREs is popular. For example, the YouTuber known as Steve1989MREInfo reviews MREs and other rations from the U.S. or other countries (such as the Individual Meal Pack), as well as vintage rations like the K-ration for content on YouTube. He gives comprehensive reviews and information about each ration he has.
continued beta cell death following diagnosis of type 1 diabetes (honeymoon period) growth spurts particularly during puberty weight gain or loss any drug treatment that affects insulin sensitivity (e.g. corticosteroids) eating, sleeping, or exercise routine changes whenever the control over hyperglycemia is degrading and according to the seasons. A pump user should be educated by their diabetes care professional about basal rate determination before beginning pump therapy.
In 1548, the house steward of Cosimo de' Medici, the grand duke of Tuscany, wrote to the Medici private secretary informing him that the basket of tomatoes sent from the grand duke's Florentine estate at Torre del Gallo "had arrived safely". Tomatoes were grown mainly as ornamentals early on after they arrived in Italy. For example, the Florentine aristocrat Giovanvettorio Soderini wrote how they "were to be sought only for their beauty", and were grown only in gardens or flower beds. The tomato's ability to mutate and create new and different varieties helped contribute to its success and spread throughout Italy. However, in areas where the climate supported growing tomatoes, their habit of growing close to the ground suggested low status. They were not adopted as a staple of the peasant population because they were not as filling as other crops. Additionally, both toxic and inedible varieties discouraged many people from attempting to consume or prepare any other varieties. In certain areas of Italy, such as Florence, the fruit was used solely as a tabletop decoration until it was incorporated into the local cuisine in the late 17th or early 18th century. The earliest discovered cookbook with tomato recipes was published in Naples in 1692, though the author had apparently obtained these recipes from Spanish sources. Varieties were developed over the following centuries for drying, for sauce, for pizzas, and for long-term storage. These varieties are usually known for their place of origin as much as by a variety name.
=== Phase 2b clinical trial – ABSSSI === Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections The study started February 2014 and announced completed enrollment 19 August 2014. Overall, 215 patients were randomized to one of three dosing regimens of brilacidin (single dose 0.6 mg/kg; single-dose 0.8 mg/kg; 1.2 mg/kg over 3 days) or 7 days of once daily daptomycin. finding that a single dose brilacidin was comparable to 7 days of daptomycin. The primary endpoint was clinical success in the intent-to-treat population, defined as reduction of at least 20% in area of the ABSSSI lesion, relative to baseline, when observed 48–72 hours after the first dose of study drug, and no rescue antibiotics administered.
Sources: en.wikipedia.org
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.
Published human trials are lacking. Most data come from cell cultures and animal models. Therefore, clinical effects and safety in people are uncertain.
It has been promoted in online communities for cognitive enhancement. That discussion is based largely on preclinical findings. It does not constitute evidence of efficacy or safety.
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.